NO20021476L - Pharmaceutical borer formulation - Google Patents

Pharmaceutical borer formulation

Info

Publication number
NO20021476L
NO20021476L NO20021476A NO20021476A NO20021476L NO 20021476 L NO20021476 L NO 20021476L NO 20021476 A NO20021476 A NO 20021476A NO 20021476 A NO20021476 A NO 20021476A NO 20021476 L NO20021476 L NO 20021476L
Authority
NO
Norway
Prior art keywords
pharmaceutical
borer
formulation
fatty acid
acid esters
Prior art date
Application number
NO20021476A
Other languages
Norwegian (no)
Other versions
NO20021476D0 (en
Inventor
Joseph Kyuwung Yoon
Richard William Saunders
Mahdi Bakir Fawzi
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20021476D0 publication Critical patent/NO20021476D0/en
Publication of NO20021476L publication Critical patent/NO20021476L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet bærersystemer nyttige for fremstilling av farmasøytiske formuleringer, idet systemene omfatter, i vektprosentandeler, fra omtrent 1 % til omtrent 20 %, fortrinnsvis fra omtrent 5 % til omtrent 12 %, av en overflateaktive middelkomponent; fra omtrent 55 % til omtrent 93 %, fortrinnsvis fra omtrent 60 % til omtrent 85, av en komponent av en eller flere polyetylenglkoler (PEG); og fra omtrent 1 % til omtrent 25 %, fortrinnsvis fra omtrent 5 % til omtrent 15 %, av "en eller flere sukrosefettsyrestere eller polybinylpyrrolidon (PVP) med en K.-verdi på mellom omtrent 15 og omtrent 90, fortrinnsvis med en K-verdi på fra omtrent 16 til omtrent 18, mest foretrukket omtrent 17, som definert i USP/NF, eller en kombina- jon av en eller flere sukrosefettsyreestere eller PVP, og eventuelt en eller flere farmasøytisk akseptable konserveringsmidler, slik som BHA, BHT, askorbyl- palmitat eller benzylalkohol.Carrier systems are disclosed useful in the preparation of pharmaceutical formulations, the systems comprising, in weight percentages, from about 1% to about 20%, preferably from about 5% to about 12%, of a surfactant component; from about 55% to about 93%, preferably from about 60% to about 85, of a component of one or more polyethylene glycol (PEG); and from about 1% to about 25%, preferably from about 5% to about 15%, of "one or more sucrose fatty acid esters or polybinylpyrrolidone (PVP) having a K value of between about 15 and about 90, preferably with a K values of from about 16 to about 18, most preferably about 17, as defined in USP / NF, or a combination of one or more sucrose fatty acid esters or PVPs, and optionally one or more pharmaceutically acceptable preservatives, such as BHA, BHT, ascorbyl - palmitate or benzyl alcohol.

NO20021476A 1999-09-27 2002-03-25 Pharmaceutical borer formulation NO20021476L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40616499A 1999-09-27 1999-09-27
PCT/US2000/026381 WO2001022942A1 (en) 1999-09-27 2000-09-26 Pharmaceutical carrier formulation

Publications (2)

Publication Number Publication Date
NO20021476D0 NO20021476D0 (en) 2002-03-25
NO20021476L true NO20021476L (en) 2002-04-16

Family

ID=23606801

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021476A NO20021476L (en) 1999-09-27 2002-03-25 Pharmaceutical borer formulation

Country Status (18)

Country Link
EP (1) EP1216029A1 (en)
JP (1) JP2003510267A (en)
KR (1) KR20020064289A (en)
CN (1) CN1399542A (en)
AR (1) AR025867A1 (en)
AU (1) AU7716100A (en)
BR (1) BR0014308A (en)
CA (1) CA2388471A1 (en)
CZ (1) CZ20021082A3 (en)
EA (1) EA200200415A1 (en)
HK (1) HK1044485A1 (en)
HU (1) HUP0202652A3 (en)
IL (1) IL148543A0 (en)
MX (1) MXPA02003190A (en)
NO (1) NO20021476L (en)
PL (1) PL354331A1 (en)
WO (1) WO2001022942A1 (en)
ZA (1) ZA200203311B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
WO2004073692A1 (en) * 2003-02-18 2004-09-02 Yamashita, Shinji Hard capsule of hardly water-soluble drug
CN100342856C (en) * 2003-04-10 2007-10-17 上海医药工业研究院 Composition of danazol semisolid skeleton preparation
US8333989B2 (en) 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
CN101351196B (en) 2005-10-26 2013-07-03 班纳制药公司 Dual controlled-release matrix system based on lipophilic carrier as capsule filling
US20100093725A1 (en) * 2006-10-31 2010-04-15 Wyeth Semi-solid formulations of phospholipase enzyme inhibitors
CN111032004B (en) * 2017-12-20 2023-10-20 弗门尼舍有限公司 Oral care compositions
EP3733826B1 (en) * 2019-05-03 2024-07-17 The Procter & Gamble Company Particle treatment compositions comprising an antioxidant
US20230414523A1 (en) * 2022-06-13 2023-12-28 R.P. Scherer Technologies, Llc Enteric bisacodyl softgel capsule

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3636123A1 (en) * 1986-10-23 1988-05-05 Rentschler Arzneimittel ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
CA2388471A1 (en) 2001-04-05
AR025867A1 (en) 2002-12-18
CZ20021082A3 (en) 2002-06-12
EA200200415A1 (en) 2002-10-31
BR0014308A (en) 2002-05-21
KR20020064289A (en) 2002-08-07
HUP0202652A2 (en) 2004-05-28
WO2001022942A1 (en) 2001-04-05
MXPA02003190A (en) 2002-09-30
HUP0202652A3 (en) 2004-06-28
PL354331A1 (en) 2004-01-12
NO20021476D0 (en) 2002-03-25
AU7716100A (en) 2001-04-30
JP2003510267A (en) 2003-03-18
ZA200203311B (en) 2003-12-31
CN1399542A (en) 2003-02-26
HK1044485A1 (en) 2002-10-25
EP1216029A1 (en) 2002-06-26
IL148543A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
CA2328950A1 (en) Piperidinopyrimidine derivatives for topical application
CY1114631T1 (en) PHARMACEUTICAL FORMS OF ECHINOCANDIN Containing surfactants that form a micelle
WO1998040069A3 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
IE871335L (en) Steroid formulations.
ITFI930247A1 (en) ANTAGONISTS OF TACHYCININS, PROCEDURE FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL FORMULATIONS.
ES2110377T1 (en) GALLENIC FORMULATION OF PHENOFIBRATE AND APPLICATION OF THE SAME.
EP0215423A3 (en) Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation
WO1998020872B1 (en) Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections
CA2058428A1 (en) Analgesic formulations
CA2337745A1 (en) Human growth hormone aqueous formulation
IL102633A0 (en) Compositions
PT918507E (en) FORMULATIONS IN AEROSOL
CA2519351A1 (en) Controlled release system
WO1999051271A3 (en) Compositions comprising glycol derivatives and alcohols
MX9204382A (en) COMPOSITIONS
EP1886691A3 (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
HK1044485A1 (en) Pharmaceutical carrier formulation
PE20030545A1 (en) RIBAVIRIN SYRUP FORMULATIONS
CA2264693A1 (en) Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation
WO2021216450A8 (en) Opioid antagonist formulations
WO2001022969A3 (en) Vasopressin agonist formulation and process
DE60017938D1 (en) PHARMACEUTICAL COMPOSITIONS AND PREPARATIONS OF ERGOTALKALOID-CONTAINING MEDICAMENTIC COMPOSITIONS WITH DELAYED ACTIVE AMOUNT AND IMPROVED BIOAVAILABILITY
JP2003526680A5 (en)
EP0056681A3 (en) Levonantradol and n-methyllevonantradol formulations
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application